Among 16 patients with this difficult-to-treat tumor "with few treatment options," the confirmed overall response rate (ORR) ...

So far, immune cells that have been engineered to kill cancers, known as CAR T-cells, haven’t worked well against solid ...

The ability of immune cells—particularly CD8+ T cells—to launch a rapid burst of proliferation inside tumors is key to the ...

Some 68% of patients with autoimmune disease had "major" side effects from CAR-T therapy for myeloma, lymphoma, or leukemia, ...

In 2015, Bluestone led a small clinical trial to isolate and grow Tregs from diabetes patients and then reinfuse the cells ...

A pan-immunotherapy biomarker predicts and reactivates CD8⁺ T cell expansion, offering new insight into treatment response.

CAR T-cell therapy shows promise for SCLC, but significant barriers, such as tumor heterogeneity and immunosuppression, must be addressed. Early research has identified several antigens that could ...

Researchers at the Medical University of Vienna have taken a closer look at a previously largely unknown component of the ...

Cemacabtagene ansegedleucel, an allogeneic chimeric antigen receptor (CAR) T-cell therapy, is being investigated in relapsed/refractory large B-cell lymphoma. The investigational allogeneic chimeric ...

Triple-negative breast cancer is one of the most aggressive cancers. The name tells the story: It lacks the three main ...